Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens
- PMID: 26493839
- PMCID: PMC4619029
- DOI: 10.1186/s12865-015-0119-7
Sequence conservation analysis and in silico human leukocyte antigen-peptide binding predictions for the Mtb72F and M72 tuberculosis candidate vaccine antigens
Abstract
Background: Requisites for an efficacious tuberculosis (TB) vaccine are a minimal genomic diversity among infectious Mycobacterium tuberculosis strains for the selected antigen, and the capability to induce robust T-cell responses in the majority of human populations. A tool in the identification of putative T-cell epitopes is in silico prediction of major histocompatibility complex (MHC)-peptide binding. Candidate TB vaccine antigen Mtb72F and its successor M72 are recombinant fusion proteins derived from Mtb32A and Mtb39A (encoded by Rv0125 and Rv1196, respectively). Adjuvanted Mtb72F and M72 candidate vaccines were shown to induce CD4(+) T-cell responses in European, US, African and Asian populations.
Methods: Sequence conservation of Mtb32A, Mtb39A, Mtb72F and M72 among 46 strains (prevalent Mycobacterium strains causing human TB disease, and H37Ra) was assessed by multiple alignments using ClustalX. For Mtb32A, Mtb39A and Mtb72F, 15-mer human leukocyte antigen (HLA)-class II-binding peptides were predicted for 158 DRB1 alleles prevailing in populations with high TB burden, 6 DRB3/4/5, 8 DQ and 6 DP alleles, using NetMHCII-pan-3.0. Results for 3 DRB1 alleles were compared with previously published allele-matched in vitro binding data. Additional analyses were done for M72. Nonameric MHC class I-binding peptides in Mtb72F were predicted for three alleles representative of class I supertypes A02, A03 and B07, using seven prediction algorithms.
Results: Sequence identity among strains was ≥98 % for each protein. Residue changes in Mtb39A comprised primarily single residue or nucleotide insertions and/or deletions in repeat regions, and were observed in 67 % of strains. For Mtb72F, 156 DRB1, 6 DRB3/4/5, 7 DQ and 5 DP alleles were predicted to contain at least one MHC class II-binding peptide, and class I-binding peptides were predicted for each HLA-A/B allele. Comparison of predicted MHC-II-binding peptides with experimental data indicated that the algorithm's sensitivity and specificity were variable among alleles.
Conclusions: The sequences from which Mtb72F and M72 are derived are highly conserved among representative Mycobacterium strains. Predicted putative T-cell epitopes in M72 and/or Mtb72F covered a wide array of HLA alleles. In silico binding predictions for class I- and II-binding putative epitopes can be complemented with biochemical verification of HLA binding capacity, processing and immunogenicity of the predicted peptides.
Figures

Similar articles
-
Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.Vaccine. 2013 Apr 19;31(17):2196-206. doi: 10.1016/j.vaccine.2012.05.035. Epub 2012 May 27. Vaccine. 2013. PMID: 22643213 Clinical Trial.
-
Identification of HLA-DRB1*09:01-restricted Mycobacterium tuberculosis CD4+ T-cell epitopes.FEBS Lett. 2016 Dec;590(24):4541-4549. doi: 10.1002/1873-3468.12478. Epub 2016 Nov 16. FEBS Lett. 2016. PMID: 27861807
-
Using epitope predictions to evaluate efficacy and population coverage of the Mtb72f vaccine for tuberculosis.BMC Immunol. 2010 Mar 30;11:18. doi: 10.1186/1471-2172-11-18. BMC Immunol. 2010. PMID: 20353587 Free PMC article.
-
Peptide binding motifs for MHC class I and II molecules.Curr Protoc Immunol. 2001 May;Appendix 1:Appendix 1I. doi: 10.1002/0471142735.ima01is36. Curr Protoc Immunol. 2001. PMID: 18432645 Review.
-
Harnessing donor unrestricted T-cells for new vaccines against tuberculosis.Vaccine. 2019 May 21;37(23):3022-3030. doi: 10.1016/j.vaccine.2019.04.050. Epub 2019 Apr 27. Vaccine. 2019. PMID: 31040086 Free PMC article. Review.
Cited by
-
RNA vaccines: The dawn of a new age for tuberculosis?Hum Vaccin Immunother. 2025 Dec;21(1):2469333. doi: 10.1080/21645515.2025.2469333. Epub 2025 Feb 27. Hum Vaccin Immunother. 2025. PMID: 40013818 Free PMC article. Review.
-
PBITV3 : A robust and comprehensive tool for screening pathogenic proteomes for drug targets and prioritizing vaccine candidates.Protein Sci. 2024 Feb;33(2):e4892. doi: 10.1002/pro.4892. Protein Sci. 2024. PMID: 38168465 Free PMC article.
-
Whole genome sequencing, analyses of drug resistance-conferring mutations, and correlation with transmission of Mycobacterium tuberculosis carrying katG-S315T in Hanoi, Vietnam.Sci Rep. 2019 Oct 25;9(1):15354. doi: 10.1038/s41598-019-51812-7. Sci Rep. 2019. PMID: 31653940 Free PMC article.
-
High Sequence Variability of the ppE18 Gene of Clinical Mycobacterium tuberculosis Complex Strains Potentially Impacts Effectivity of Vaccine Candidate M72/AS01E.PLoS One. 2016 Mar 24;11(3):e0152200. doi: 10.1371/journal.pone.0152200. eCollection 2016. PLoS One. 2016. PMID: 27011018 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous